| Abstract |
Objective To study the clinical effect of high frequency rTMS assistant lifujunan in the treatment of senile severe schizophrenia. Methods From June 2015 to August 2018, 89 patients with severe schizophrenia in our hospital were enrolled. The patients were divided into two groups according to the random number table (n=45) and the drug group (n=44). The drug group was treated with ziprasidone hydrochloride tablets, and the combination group was treated with ziprasidone hydrochloride tablets and high frequency rTMS. Compare two groups of efficacy, adverse reactions, symptoms before treatment and 2 months after treatment (positive symptom score, negative symptom score), serum glial fibrillary acidic protein (GFAP), brain-derived neurotrophic factor (BDNF), nerve growth Factor (NGF) level. Results (1) Efficacy: The total effective rate was 93.33% (42/45), which was higher than 77.27% (34/44) in the drug group (P<0.05). (2) Symptoms: 2 months after treatment Positive and negative symptom scores were significantly improved, and the combination group was lower than the drug group (P<0.05). (3) Serum GFAP, BDNF, NGF levels: serum GFAP levels in the combined group were lower than those in the drug group after 2 months of treatment, serum BDNF The level of NGF was higher than that of the drug group (P<0.05); (4) Adverse reactions: all adverse reactions were mild and did not affect treatment; the incidence of adverse reactions in the combined group was 2.22% (1/45) and 4.55% in the drug group (2 /44) Contrast, the difference was not statistically significant (P>0.05). Conclusion Ziprasidone hydrochloride tablets combined with high-frequency rTMS have a significant regulatory effect on serum factors, which can further improve the efficacy of severe schizophrenia in the elderly, improve clinical symptoms, and have a low incidence of adverse reactions and high safety.
|